ARWR vs. AXSM, CYTK, RARE, OGN, PBH, HCM, INSM, ZLAB, EVO, and NUVL
Should you be buying Arrowhead Pharmaceuticals stock or one of its competitors? The main competitors of Arrowhead Pharmaceuticals include Axsome Therapeutics (AXSM), Cytokinetics (CYTK), Ultragenyx Pharmaceutical (RARE), Organon & Co. (OGN), Prestige Consumer Healthcare (PBH), HUTCHMED (HCM), Insmed (INSM), Zai Lab (ZLAB), Evotec (EVO), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical preparations" industry.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Axsome Therapeutics (NASDAQ:AXSM) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, community ranking, dividends, valuation, institutional ownership and earnings.
Arrowhead Pharmaceuticals has a net margin of -85.27% compared to Axsome Therapeutics' net margin of -90.33%. Arrowhead Pharmaceuticals' return on equity of -53.65% beat Axsome Therapeutics' return on equity.
66.0% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.6% of Axsome Therapeutics shares are owned by institutional investors. 5.0% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 24.5% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Arrowhead Pharmaceuticals has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 1.95, suggesting that its share price is 95% more volatile than the S&P 500.
In the previous week, Arrowhead Pharmaceuticals had 17 more articles in the media than Axsome Therapeutics. MarketBeat recorded 19 mentions for Arrowhead Pharmaceuticals and 2 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 1.15 beat Arrowhead Pharmaceuticals' score of 0.41 indicating that Axsome Therapeutics is being referred to more favorably in the news media.
Arrowhead Pharmaceuticals presently has a consensus target price of $53.00, indicating a potential upside of 128.74%. Axsome Therapeutics has a consensus target price of $105.50, indicating a potential upside of 55.15%. Given Arrowhead Pharmaceuticals' higher probable upside, equities analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Axsome Therapeutics.
Arrowhead Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Arrowhead Pharmaceuticals received 122 more outperform votes than Axsome Therapeutics when rated by MarketBeat users. However, 67.18% of users gave Axsome Therapeutics an outperform vote while only 65.20% of users gave Arrowhead Pharmaceuticals an outperform vote.
Summary
Arrowhead Pharmaceuticals beats Axsome Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Arrowhead Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARWR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Arrowhead Pharmaceuticals Competitors List
Related Companies and Tools